European Medicines Agency receives mainly favorable evaluation from Ernst & Young

A year-long evaluation process designed to assess the effectiveness and efficiency of the European Medicines Agency's (EMEA) operations has concluded with a largely favorable outcome for the Agency and its partner organizations in the European Union member states.

The evaluation, conducted by Ernst & Young at the request of the European Commission, concluded that the Agency "has proved effective in protecting public and animal health by providing the EU citizens with human and veterinary medicinal products fulfilling the requirements for quality, safety and efficacy and has clearly contributed to the harmonization of [the] EU internal market for medicines."

Since its creation in 1993, the EMEA has made considerable progress in maintaining an effective European authorization system for human and veterinary medicinal products. In a quite limited timeframe, the EMEA has gained great consideration from all stakeholders, at European as well as at international level, the report noted.